+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety, tolerability, and immune response of the rVSV94G-LASV-GPC vaccine in adults and children living in West Africa. This Phase 2 clinical trial builds on earlier studies that showed the vaccine to be safe and able to protect animals against Lassa Fever. The study includes healthy adults, HIV-infected adults, adolescents, and children to better understand the vaccines effects across these groups and prepare for future effectiveness trials. Participants will receive one of three different doses of the rVSV94G-LASV-GPC vaccine or a placebo in a randomized, double-blinded manner. The vaccine is given as a single dose on Day 1. The study includes separate cohorts for healthy adults aged 18-70, HIV-infected adults aged 18-50, adolescents aged 12-17, and children aged 6-11. The study will observe vaccine safety and immune responses over various time points up to 7 months and beyond in some cases. During the study, participants will undergo medical exams, HIV testing, and monitoring for vaccine-related side effects. Researchers will measure antibody responses, vaccine presence in blood and body fluids, and immune system characteristics. Participants will be followed for safety and the duration of immune responses for up to 30 months in some cases. The study aims to provide detailed information on how well the vaccine is tolerated and how it stimulates the immune system in different age and health groups.

Age: 6Years - 70YearsAll GendersPhase 2
3 locations
L

Actively Recruiting

Researchers are evaluating etavopivat, a new oral medicine being developed for blood disorders such as sickle cell disease and thalassaemia. These inherited conditions affect hemoglobin, the protein responsible for carrying oxygen in the body. This long-term study aims to assess the safety and effectiveness of etavopivat treatment over a period of up to 264 weeks, or until the drug is approved in the participants country. Participants will receive one of several oral doses of etavopivat, with dosing adjusted by age those 12 years and older will receive Etavopivat A or C, while children younger than 12 years will receive Etavopivat B. The study involves multiple groups including adults, adolescents, and children with different types of sickle cell disease or thalassaemia. All participants have completed a prior etavopivat treatment study and are continuing treatment in this rollover study. During the study, participants will be regularly monitored for treatment-related side effects and clinical benefits. Researchers will track adverse events, blood crisis rates, hemoglobin levels, hospitalizations, and blood transfusion needs. The study includes long-term safety and efficacy assessments conducted over several years, with monitoring continuing until study completion or drug approval. Participants health and treatment responses will be carefully followed throughout this extended period.

Age: 2Years +All GendersPhase 3
107 locations
G

Actively Recruiting

Researchers are evaluating etavopivat in adolescents and adults with sickle cell disease to see if it can reduce vaso-occlusive crises painful blockages in blood vessels and protect organs from damage. This phase 3 study will also assess whether etavopivat improves exercise tolerance and reduces fatigue compared to a placebo. The trial is randomized, double-blind, and placebo-controlled to ensure unbiased results on the medications effects. Participants will be randomly assigned to receive either oral etavopivat or a matching placebo. The study treatment is taken by mouth, and participants will be followed closely for about 2 years. This includes monitoring during the treatment period and ongoing assessments to evaluate the drugs impact on sickle cell disease symptoms and related health measures. Throughout the study, participants will undergo evaluations such as blood tests to measure hemoglobin and other markers, 6-minute walking tests to assess exercise capacity, and fatigue questionnaires. Researchers will track the number of vaso-occlusive crises requiring medical contact over 52 weeks as the primary outcome. Safety and efficacy will be monitored regularly, with follow-up continuing until the study ends approximately 4 years after enrollment begins.

Age: 12Years +All GendersPhase 3
175 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are studying blood-based protein markers and heart ultrasound patterns in pregnant women with preeclampsia to detect early heart changes even before symptoms appear. The study aims to understand how these blood markers relate to heart function changes seen on ultrasound and how they might help predict future health problems for the mother. This observational study will recruit about 172 women up to 20 weeks pregnant who are part of another study called ENHANCE-CVH. Participants will undergo transthoracic echocardiography heart ultrasound twice during pregnancy, at 12-16 weeks and again at 28-32 weeks. Blood samples will also be collected at these two time points to measure over 5,400 proteins for analysis. The study will compare these protein patterns with echocardiographic measures of heart structure and function, looking for links with pregnancy outcomes, especially preeclampsia and peripartum heart failure. During the study, participants will complete a 20-minute survey about their health history and undergo physical measurements including height, weight, and blood pressure. Echocardiograms will be performed by trained cardiologists at a cardiology unit, and blood samples will be processed and stored for protein analysis. The main outcomes measured are the proteomic markers and cardiac phenotypes at the two pregnancy stages. The study plans to complete in December 2027.

Age: 13Years - 50YearsFEMALE
1 location
S

Actively Recruiting

Tuberculosis TB remains a major global health issue with over 3 million undiagnosed cases and 1 million deaths annually. This research aims to improve TB diagnosis by evaluating faster, simpler, and less expensive point-of-care tests that do not rely on sputum samples. The study focuses on adolescents and adults with symptoms or risk factors for TB presenting at outpatient clinics in high-burden countries. Participants will be tested using novel TB triage and diagnostic tools, including tongue swab-based molecular assays designed for near point-of-care use. The study will compare these new tests against established methods like sputum Xpert MTBRIF Ultra and mycobacterial culture. Additionally, the usability and acceptability of these tests will be assessed by observing and surveying health workers involved in routine TB testing. Participants will undergo screening for TB symptoms or risk factors and provide samples for diagnostic testing. Researchers will evaluate how often the new tests correctly identify TB cases and non-cases over two years. Health workers will be surveyed to understand the ease and practicality of using the new tests. The study is expected to continue until September 2028, with ongoing monitoring of test performance and user feedback.

Age: 12Years +All GendersPhase Not Applicable
3 locations
I

Actively Recruiting

Researchers are evaluating diabetes management within the Hypertension Treatment in Nigeria HTN 2.0 Program, building on prior success in hypertension care. The study focuses on 10 primary healthcare centers in Nigerias Federal Capital Territory that previously implemented hypertension treatment. This phase uses the WHO HEARTS-D bundle to improve diabetes screening, diagnosis, treatment, and control in these centers. The study compares a 12-month pre-implementation period, which involves registry setup and providing glucometers without diabetes treatment training, to a 24-month implementation period. During implementation, the centers receive HEARTS-D training for community health extension workers, expand drug availability including metformin and glimepiride, and receive quarterly supportive supervision with audit-and-feedback. Glucometers and supplies are replenished throughout the study. Participants include adults with or at risk for diabetes attending these centers. Researchers will monitor blood glucose control, diabetes treatment rates, and availability of diabetes medicines and equipment. Assessments include routine blood glucose measurements and registration of diabetes patients. Supportive supervision visits and training aim to improve care quality over 36 months, with outcomes measured by changes in blood glucose control and treatment adherence.

Age: 18Years +All GendersPhase Not Applicable
10 locations
C

Actively Recruiting

Healthy Volunteer

This research aims to evaluate two training protocols designed to improve a physicians ability to screen and treat high-grade intraepithelial lesions HSILs to prevent anal cancer. The study focuses on comparing the current standard training developed in high-income countries with a new training tailored specifically for the Nigerian healthcare setting. The goal is to determine if the tailored training leads to better performance in anal cancer screening and treatment within an HIV care context. The study will first apply the standard training for 12 months to observe baseline screening and treatment practices. Then, an enhanced training called e-STH, developed through an iterative process based on local barriers and facilitators, will be implemented over 6 months. Following this, a 12-month period will evaluate the impact of the enhanced training on HSIL detection and treatment. Finally, a 6-month phase will assess the sustainability of the improved screening and treatment practices with minimal involvement from the research team. Participants involved are a single physician undergoing these training protocols at one clinic. Researchers will monitor the proportion of HSIL cases detected and treated, as well as secondary outcomes related to reach, efficacy, implementation, and sustainability of the screening program. The study uses a non-randomized, sequential design to evaluate these outcomes over a total period of 36 months, with ongoing assessments throughout each phase.

All AgesAll GendersPhase Not Applicable
1 location
I

Actively Recruiting

Researchers are studying the best ways to develop and use a management package for women with Hypertensive Disorders of Pregnancy HDP in Nigeria. The study aims to find out if a home blood pressure BP monitoring program, tailored for local needs, can improve BP control and cardiovascular health for pregnant women with HDP. This project is conducted at four health institutions in Abuja and Kano, Nigeria. The study has two phases. During the control phase, baseline data like postpartum BP measurements and treatments are recorded. After 12 months, participants switch to the intervention phase where they receive the HDP Implementation Bundle. This bundle includes patient education about BP and HDP risks, training on home BP monitoring with a free automated BP monitor, a standardized follow-up plan, and free antihypertensive medications if needed. Participants will have their BP measured and recorded at enrollment, and again at 6 and 12 weeks postpartum. The study measures differences in systolic and diastolic BP between the control and intervention phases. The researchers will also evaluate how well the program is accepted and followed. This study runs until June 2029, with ongoing monitoring of participants cardiovascular health and BP control.

All AgesFEMALEPhase Not Applicable
4 locations
I

Actively Recruiting

Healthy Volunteer

This research aims to improve the use of hydroxyurea HU for managing sickle cell disease SCD in Nigeria, where most patients currently do not receive evidence-based care despite HUs potential to reduce complications and mortality. The study addresses provider barriers to HU adoption using a practical approach based on previous NIH-funded trials and Nigerian health guidelines. It focuses on increasing HU adoption by healthcare providers through a tailored strategy in clinical settings. The study compares two approaches at 20 clinical sites one group receives educational information about task sharing SIM, and the other group receives an enhanced strategy called TASSH TCP, which includes healthcare worker training, clinical reminders, and practice facilitation to support SCD management. The study follows a cluster randomized design to assess which approach leads to better adoption of HU treatment over 12 months. The implementation and sustainability of these methods are also evaluated at 12 and 24 months. Participants include SCD patients registered at local clinical sites, with assessments including screening, HU treatment initiation, and dosage monitoring at 12 months. Data on adoption rates, implementation fidelity, and mediators affecting these outcomes are collected. The study will help identify scalable and sustainable ways to improve HU use in Nigeria and monitor patient outcomes through electronic medical records over the study period, which runs until May 2028.

Age: 12Months +All GendersPhase Not Applicable
1 location
G

Actively Recruiting

Researchers are conducting an observational, multicenter, international study to learn about antimicrobial resistance AMR in people with chronic lung diseases CLD worldwide. The study aims to understand how common AMR is in these patients, how it varies by location, and what risk factors contribute to it. This study is non-pharmacological and collects data without adding any new treatments or procedures beyond usual care. Data will be collected at multiple centers during two separate two-week periods each year for five years. Participants include patients of all ages with chronic lung diseases who have had at least one respiratory sample collected within the past year. Clinical, demographic, and microbiological information will be gathered through questionnaires and medical records, all recorded in a secure electronic system. No additional tests or interventions outside routine clinical practice will be performed. Participants will provide informed consent before joining. Throughout the study, researchers will monitor the prevalence of antimicrobial resistance and analyze susceptibility patterns of key resistant pathogens, geographical differences, and risk factors for AMR by reviewing collected clinical and microbiological data. The study will last five years, with data collected periodically and securely maintained to better understand AMRs impact on chronic lung diseases.

All AgesAll Genders
68 locations

1-10 of 14

1